Kailera Therapeutics, Inc.

The Company believes the cash, cash equivalents and marketable securities on hand of $ 1,171.8 million as of June 30, 2026 will be sufficient to fund its operations and capital expenditure requirements for at least twelve months from the date these condensed consolidated financial statements are issued.

SEC original ↗Kailera Therapeutics, Inc. — 10-Q Quarterly report10-QAug 12, 2026

The Company has not paid, and does not anticipate paying, cash dividends on its common stock; therefore, the expected dividend yield is assumed to be zero.

SEC original ↗Kailera Therapeutics, Inc. — 10-Q Quarterly report10-QAug 12, 2026

The Company would cease to be an emerging growth company if it has more than $1.235 billion in annual revenue, if it has more than $700.0 million in market value of our stock held by non-affiliates (and it has been a public company for at least 12 months and has filed one annual report on Form 10-K) or the Company issues more than $1.0 billion of non-convertible debt securities over a three-year period.

SEC original ↗Kailera Therapeutics, Inc. — 10-Q Quarterly report10-QAug 12, 2026

government agency debt securities $ 248,546 $ $ ( 359 ) $ 248,187 Corporate debt securities 296,772 1 ( 620 ) 296,153 Commercial paper 242,318 6 ( 224 ) 242,100 $ 787,636 $ 7 $ ( 1,203 ) $ 786,440 Long-term marketable securities: U.

SEC original ↗Kailera Therapeutics, Inc. — 10-Q Quarterly report10-QAug 12, 2026

government agency debt securities $ 138,073 $ 14 $ ( 303 ) 137,784 Corporate debt securities 117,599 ( 307 ) 117,292 $ 255,672 $ 14 $ ( 610 ) $ 255,076 December 31, 2025 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Marketable securities: U.

SEC original ↗Kailera Therapeutics, Inc. — 10-Q Quarterly report10-QAug 12, 2026

government agency debt securities $ 169,690 $ 108 $ $ 169,798 Corporate debt securities 122,737 23 ( 47 ) 122,713 Commercial paper 93,241 37 93,278 $ 385,668 $ 168 $ ( 47 ) $ 385,789 Long-term marketable securities: U.

SEC original ↗Kailera Therapeutics, Inc. — 10-Q Quarterly report10-QAug 12, 2026

(Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today reported financial results for the first quarter ended March 31, 2026, and provided a summary of recent business highlights.

SEC original ↗Kailera Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99May 26, 2026

We are focused on maintaining this momentum and executing across our clinical programs as we work to deliver differentiated therapies for the treatment of obesity.

SEC original ↗Kailera Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99May 26, 2026

Liu, China Head of Corporate Development at Hengrui, brings expertise in evaluating R&D innovation and advising on corporate development strategy across the healthcare industry.

SEC original ↗Kailera Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99May 26, 2026

Upcoming Events Kailera expects to participate in the following investor conferences and medical congresses: • Jefferies Global Healthcare Conference – June 4, 2026 • American Diabetes Association Scientific Sessions – June 5-8, 2026 About Kailera Therapeutics Kailera Therapeutics (Kailera) is a clinical-stage biotechnology company focused on elevating the next era of obesity care by progressing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey.

SEC original ↗Kailera Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99May 26, 2026

All statements contained in this Quarterly Report on Form 10-Q that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding our future results of operations and financial position, business strategy, product candidate development, prospective products, product candidate approvals, research and development activities and costs, future revenue, timing and likelihood of success of our business plans, plans and objectives of management, future results and timing of clinical trials, treatment potential of our product candidates, and the market potential of our product candidates.

SEC original ↗Kailera Therapeutics, Inc. — 10-Q Quarterly report10-QAug 12, 2026

Forward-looking statements are based on current expectations and assumptions together with projections of the future which are inherently uncertain, and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied.

SEC original ↗Kailera Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99May 26, 2026

These risks and uncertainties include, among others, uncertainties inherent in clinical development, regulatory review, manufacturing, competition, market opportunities, reliance on third parties, estimates of capital requirements, needs for additional financing, and other important factors, including those discussed under the caption “Risk Factors” in Kailera’s filings with the Securities and Exchange Commission.

SEC original ↗Kailera Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99May 26, 2026

These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

SEC original ↗Kailera Therapeutics, Inc. — 10-Q Quarterly report10-QAug 12, 2026

These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of risks, uncertainties and assumptions described in the section titled Risk Factors and elsewhere in this Quarterly Report on Form 10-Q.

SEC original ↗Kailera Therapeutics, Inc. — 10-Q Quarterly report10-QAug 12, 2026

In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all.

SEC original ↗Kailera Therapeutics, Inc. — 10-Q Quarterly report10-QAug 12, 2026

SUMMARY OF RISKS ASSOCIATED WITH OUR BUSINESS Our business is subject to numerous risks and uncertainties that you should be aware of before making an investment decision, including those described in Part II, Item 1A.

SEC original ↗Kailera Therapeutics, Inc. — 10-Q Quarterly report10-QAug 12, 2026